Targeted OncologyCMB305 Immunotherapy Regimen Demonstrates 83% OS Rate in Sarcoma, 1-Year Data ShowsTargeted OncologyCMB305, an immunotherapy regimen that generates and expands anti-NY-ESO-1 T cells, demonstrated a favorable survival rate in patients w… Continue reading
Scicasts (press release) (blog)Antibody Study Suggests a Better Way to Make Stem CellsScicasts (press release) (blog)11 in an Advance Online paper in Nature Biotechnology, the TSRI scientists screened a library of 100 million antibodies and found sever… Continue reading
Indo-Japan Collaboration expands to scale up research to translationsBusiness StandardHe added that while Japan stands out with the expertise of its scientists in areas like stem cell research, India can offer its young science brains that can be train… Continue reading
ChronicleLive |
Newcastle firm uses seaweed to transport stem cells in ground breaking new system
ChronicleLive Atelerix’s new system makes it simpler to transport cells used in stem cell therapy, and allows them to be delivered in a ready to use format. Scientific founder, professor Che Connon of Newcastle University, has been working on the technology for five … Atelerix stems from Newcastle researchGlobal University Venturing |
PLoS Blogs (blog) |
Gene Therapy and September Scenes
PLoS Blogs (blog) Today I’m giving an invited lecture at Georgia College, “Gene Therapy: A Forever Fix”? I’ve given the talk many times, since my book The Forever Fix was published in 2012, but this is the first time I won’t cry. That’s because the first children who … |
|
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Nasdaq ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The study … |